CytoReason, a pioneer in computational disease models for predictive insights, has secured $80 million from OurCrowd, NVIDIA (Nasdaq: NVDA), Pfizer (NYSE: PFE), and Thermo Fisher Scientific (NYSE: TMO).
“This investment underscores the potential of computational disease models to revolutionize data usage in pharma R&D,” said a spokesperson from Thermo Fisher. “By leveraging Thermo Fisher’s extensive data and life sciences expertise with CytoReason’s AI technology, we aim to redefine personalized healthcare.”
The funding will fuel CytoReason’s expansion into new indications, enhance its proprietary molecular and clinical data, and establish an office in Cambridge, Massachusetts later this year.
Speed, safety, and accuracy in R&D decisions are crucial for life sciences companies. CytoReason provides molecular-level insights and AI tools to optimize R&D portfolios and increase the likelihood of phase 2 success.
Since expanding its partnership with Pfizer in 2022, CytoReason has formed three new major pharma collaborations, broadened its disease model coverage to include CNS-related diseases, and partnered with leading data organizations.
CytoReason’s scientific advancements are regularly featured in prestigious journals, demonstrating the team’s expertise and technological progress.
David Harel, CEO of CytoReason, expressed gratitude for the investment, highlighting CytoReason’s leadership in data modeling for pharma R&D.
NVIDIA’s Kimberly Powell emphasized the impact of their collaboration in accelerating clinical insights.
Pfizer’s Mikael Dolsten highlighted the potential of AI to transform healthcare.
Thermo Fisher’s Bhooshi De Silva underlined the strategic importance of computational disease models in advancing personalized medicine.
Jon Medved of OurCrowd celebrated CytoReason’s role in AI healthcare innovation.
CytoReason aims to leverage this funding to accelerate growth, empower more pharma companies, and benefit patients worldwide.
For structured financing, Bank Hapoalim’s Tech Sector, Business Banking Division played a crucial role, with Nomura International Plc and Locust Walk advising on the transaction.
About CytoReason:
CytoReason transforms biopharma decision-making with computational disease models, enhancing R&D efficiency from target prioritization to patient stratification and portfolio optimization.
